Should I buy or sell Inari Medical stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NARI shares. View NARI analyst ratings or view top-rated stocks .

What is Inari Medical's stock price target for 2024?

6 analysts have issued 1-year target prices for Inari Medical's stock. Their NARI share price targets range from $52.00 to $100.00. On average, they predict the company's stock price to reach $73.71 in the next year. This suggests a possible upside of 91.0% from the stock's current price. View analysts price targets for NARI or view top-rated stocks among Wall Street analysts .

How have NARI shares performed in 2024?

Inari Medical's stock was trading at $64.92 on January 1st, 2024. Since then, NARI stock has decreased by 40.6% and is now trading at $38.59. View the best growth stocks for 2024 here .

When is Inari Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024. View our NARI earnings forecast .

How can I listen to Inari Medical's earnings call?

Inari Medical will be holding an earnings conference call on Tuesday, April 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Inari Medical's earnings last quarter?

Inari Medical, Inc. (NASDAQ:NARI) issued its earnings results on Wednesday, February, 28th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by $0.09. The firm earned $132.10 million during the quarter, compared to the consensus estimate of $131.82 million. Inari Medical had a negative net margin of 0.33% and a positive trailing twelve-month return on equity of 1.23%. The company's revenue was up 22.5% compared to the same quarter last year. During the same period last year, the business earned ($0.11) earnings per share.

What ETFs hold Inari Medical's stock?

ETFs with the largest weight of Inari Medical (NASDAQ:NARI) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS) , Motley Fool Small-Cap Growth ETF (TMFS) , Clough Select Equity ETF (CBSE) , Invesco S&P SmallCap Health Care ETF (PSCH) , Clough Long/Short Equity ETF (CBLS) , SPDR S&P Health Care Equipment ETF (XHE) , Principal Healthcare Innovators ETF (BTEC) and IQ Healthy Hearts ETF (HART) .

What guidance has Inari Medical issued on next quarter's earnings?

Inari Medical updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $580.0 million-$595.0 million, compared to the consensus revenue estimate of $588.3 million.

What other stocks do shareholders of Inari Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA) , Home Depot (HD) , CVS Health (CVS) , QUALCOMM (QCOM) , Thermo Fisher Scientific (TMO) , Johnson & Johnson (JNJ) , Alibaba Group (BABA) , Procter & Gamble (PG) and Bristol-Myers Squibb (BMY) .

When did Inari Medical IPO?

Inari Medical (NARI) raised $110 million in an initial public offering on Friday, May 22nd 2020. The company issued 7,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.

Who are Inari Medical's major shareholders?

Inari Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.05%) and Handelsinvest Investeringsforvaltning (0.00%). Insiders that own company stock include Andrew Hykes , Ansbert Gadicke, Donald B Milder , Mitch C Hill, Mitch C Hill , Stanley Tang, Thomas Tu and William Hoffman . View institutional ownership trends .

How do I buy shares of Inari Medical?

Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NARI

Inari Medical (NARI) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free NARI Stock Alerts

$38.59

-0.05 (-0.13%)

(As of 04/19/2024 ET)

Compare

Today's Range: $38.01
▼
$39.15
50-Day Range: $38.59
▼
$59.03
52-Week Range: $37.92
▼
$71.85

Volume: 802,173 shs
Average Volume: 1.13 million shs
Market Capitalization: $2.24 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $73.71

Get Inari Medical alerts:

Inari Medical MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 91.0% Upside
$73.71 Price Target
Short Interest: Bearish
8.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.19
Based on 11 Articles This Week
Insider Trading: Selling Shares
$1.95 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.39) to $0.37 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.09 out of 5 stars

Medical Sector

549th out of 911 stocks

Surgical & Medical Instruments Industry

61st out of 97 stocks

3.3

Analyst's Opinion

Consensus Rating
Inari Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Inari Medical has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.06% of the float of Inari Medical has been sold short.
Short Interest Ratio / Days to Cover
Inari Medical has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Inari Medical has recently increased by 11.45%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Inari Medical does not currently pay a dividend.
Dividend Growth
Inari Medical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NARI.

1.8

News and Social Media Coverage

News Sentiment
Inari Medical has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Inari Medical this week, compared to 4 articles on an average week.
Search Interest
Only 6 people have searched for NARI on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Inari Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inari Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,949,000.00 in company stock.
Percentage Held by Insiders
10.60% of the stock of Inari Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
90.98% of the stock of Inari Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Inari Medical are expected to grow in the coming year, from ($0.39) to $0.37 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Inari Medical is -1,286.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Inari Medical is -1,286.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Inari Medical has a P/B Ratio of 4.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Inari Medical Stock (NASDAQ:NARI)

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

NARI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NARI Stock News Headlines

April 19, 2024 | insidertrades.com

Inari Medical, Inc. (NASDAQ:NARI) Director Sells $58,040.00 in Stock

April 19, 2024 | insidertrades.com

Mitch C. Hill Sells 6,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 21, 2024 | insidertrades.com

Insider Selling: Inari Medical, Inc. (NASDAQ:NARI) Director Sells 40,000 Shares of Stock

April 18, 2024 | prnewswire.com

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Inari Medical, Inc. and Encourages Investors with Losses to Contact the Firm

April 18, 2024 | investing.com

Inari Medical CFO sells shares worth $245,760

April 17, 2024 | globenewswire.com

Inari Medical to Announce First Quarter 2024 Financial Results

April 14, 2024 | americanbankingnews.com

Inari Medical's (NARI) Buy Rating Reiterated at Canaccord Genuity Group

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 11, 2024 | globenewswire.com

Inari Medical Announces the Release of 2023 Ethos and Sustainability Report

April 10, 2024 | markets.businessinsider.com

Elucent Medical Secures Series C Funding to Advance Oncologic Surgery Innovation

April 2, 2024 | globenewswire.com

Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives

March 30, 2024 | msn.com

Market Cap Game Show: Andy Cross vs. Bill Mann

March 25, 2024 | marketwatch.com

Inari Medical Shares Gain After Index Move

March 23, 2024 | morningstar.com

Inari Medical, Inc. (NARI) Plummets on News of DOJ Investigation – Hagens Berman

March 22, 2024 | markets.businessinsider.com

Forecasting The Future: 7 Analyst Projections For Inari Medical

March 20, 2024 | finance.yahoo.com

Director William Hoffman Sells 40,000 Shares of Inari Medical Inc (NARI)

March 20, 2024 | stockhouse.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Inari Medical, Inc. (NARI) and Encourages Investors with Losses to Contact the Firm

March 19, 2024 | finance.yahoo.com

NARI Apr 2024 65.000 call

March 19, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Inari Medical, Inc.- NARI

March 16, 2024 | investing.com

Inari Medical CFO sells shares worth over $250k

March 16, 2024 | finanznachrichten.de

Inari Medical, Inc.: Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry

March 12, 2024 | globenewswire.com

Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry

March 12, 2024 | prnewswire.com

NARI INVESTOR NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Inari Medical, Inc. Investors to Inquire About Securities Class Action Investigation - NARI

March 12, 2024 | prnewswire.com

Inari Medical Investigation: Kessler Topaz Meltzer & Check, LLP Investigates The Inari Medical, Inc. (NASDAQ: NARI) for Potential Securities Violations

March 11, 2024 | businesswire.com

Inari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

March 11, 2024 | businesswire.com

Inari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

See More Headlines

Receive NARI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inari Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Confirmed): 4/30/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:NARI
CUSIP: N/A
CIK: 1531048
Web: www.inarimedical.com
Phone: 877-923-4747
Fax: N/A
Employees: 1,300
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $73.71
High Stock Price Target: $100.00
Low Stock Price Target: $52.00
Potential Upside/Downside: +90.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,640,000.00
Net Margins: -0.33%
Pretax Margin: 0.86%
Return on Equity: 1.23%
Return on Assets: 0.97%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.09
Quick Ratio: 2.52

Sales & Book Value

Annual Sales: $493.63 million
Price / Sales: 4.54
Cash Flow: $0.09 per share
Price / Cash Flow: 438.90
Book Value: $8.07 per share
Price / Book: 4.79

Miscellaneous

Outstanding Shares: 57,960,000
Free Float: 51,817,000
Market Cap: $2.24 billion
Optionable: Optionable
Beta: 0.84

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Andrew J. Hykes (Age 50)
CEO, President & Director
Comp: $1.54M
Mr. Mitchell C. Hill (Age 65)
Chief Financial Officer
Comp: $864.63k
Dr. Thomas M. Tu M.D. (Age 51)
Chief Medical Officer
Comp: $865.63k
Mr. Paul A. Koehn (Age 61)
Senior Vice President of Operations
Mr. Kevin Strange
Senior Vice President of Finance, Accounting, Strategy & Business Development
Mr. John Hsu C.F.A.
Vice President of Investor Relations
Ms. Angela Ahmad
General Counsel & Secretary
Mr. Eric Khairy
Senior Vice President of Marketing
Mr. John R. Borrell (Age 57)
Senior Vice President of Sales
Ms. Tara Dunn
Senior VP & GM of LimFlow

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NARI Stock Analysis - Frequently Asked Questions

Should I buy or sell Inari Medical stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NARI shares.
View NARI analyst ratings or view top-rated stocks.
What is Inari Medical's stock price target for 2024?: 6 analysts have issued 1-year target prices for Inari Medical's stock. Their NARI share price targets range from $52.00 to $100.00. On average, they predict the company's stock price to reach $73.71 in the next year. This suggests a possible upside of 91.0% from the stock's current price.
View analysts price targets for NARI or view top-rated stocks among Wall Street analysts.
How have NARI shares performed in 2024?: Inari Medical's stock was trading at $64.92 on January 1st, 2024. Since then, NARI stock has decreased by 40.6% and is now trading at $38.59.
View the best growth stocks for 2024 here.
When is Inari Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our NARI earnings forecast.
How can I listen to Inari Medical's earnings call?: Inari Medical will be holding an earnings conference call on Tuesday, April 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Inari Medical's earnings last quarter?: Inari Medical, Inc. (NASDAQ:NARI) issued its earnings results on Wednesday, February, 28th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by $0.09. The firm earned $132.10 million during the quarter, compared to the consensus estimate of $131.82 million. Inari Medical had a negative net margin of 0.33% and a positive trailing twelve-month return on equity of 1.23%. The company's revenue was up 22.5% compared to the same quarter last year. During the same period last year, the business earned ($0.11) earnings per share.

What ETFs hold Inari Medical's stock?: ETFs with the largest weight of Inari Medical (NASDAQ:NARI) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), Clough Select Equity ETF (CBSE), Invesco S&P SmallCap Health Care ETF (PSCH), Clough Long/Short Equity ETF (CBLS), SPDR S&P Health Care Equipment ETF (XHE), Principal Healthcare Innovators ETF (BTEC) and IQ Healthy Hearts ETF (HART).
What guidance has Inari Medical issued on next quarter's earnings?: Inari Medical updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $580.0 million-$595.0 million, compared to the consensus revenue estimate of $588.3 million.
What other stocks do shareholders of Inari Medical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Procter & Gamble (PG) and Bristol-Myers Squibb (BMY).
When did Inari Medical IPO?: Inari Medical (NARI) raised $110 million in an initial public offering on Friday, May 22nd 2020. The company issued 7,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.
Who are Inari Medical's major shareholders?: Inari Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.05%) and Handelsinvest Investeringsforvaltning (0.00%). Insiders that own company stock include Andrew Hykes, Ansbert Gadicke, Donald B Milder, Mitch C Hill, Mitch C Hill, Stanley Tang, Thomas Tu and William Hoffman.
View institutional ownership trends.
How do I buy shares of Inari Medical?: Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NARI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial